1. Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study
- Author
-
Niederwieser, Dietger, Hoffmann, Verena Sophia, Pfirrmann, Markus, Al-Ali, Haifa Kathrin, Schwind, Sebastian, Vucinic, Vladan, Krahl, Rainer, Kahl, Christoph, Wolf, Hans-Heinrich, Kreibich, Ute, Hähling, Detlef, Hegenbart, Ute, Hirt, Carsten, Peter, Norma, Florschuetz, Axel, Reifenrath, Kolja, Schulze, Antje, Zojer, Niklas, Scholl, Sebastian, Junghanss, Christian, Pönisch, Wolfram, Heyn, Simone, Sayer, Herbert G., Hochhaus, Andreas, Heinicke, Thomas, Fischer, Thomas, Krämer, Alwin, Dreger, Peter, Maschmeyer, Georg, Krug, Utz, Sauerland, Maria Christina, Heinecke, Achim, Hehlmann, Rüdiger, Lengfelder, Eva, Hiddemann, Wolfgang, Serve, Hubert, Müller-Tidow, Carsten, Berdel, Wolfgang E, and Büchner, Thomas
- Abstract
Niederwieser: Novartis Oncology Europe: Research Funding, Speakers Bureau; Amgen: Speakers Bureau. Hoffmann:Novartis Oncology Europe: Research Funding. Al-Ali:Celgene: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding. Hegenbart:Pfizer: Other: Travel grant; Janssen: Honoraria, Other: Travel grant. Sayer:Riemser Pharma: Consultancy. Hochhaus:BMS: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; ARIAD: Honoraria, Research Funding. Fischer:Novartis: Consultancy, Honoraria. Dreger:Novartis: Consultancy; Janssen: Consultancy; Gilead: Consultancy; Gilead: Speakers Bureau; Roche: Consultancy; Novartis: Speakers Bureau. Hiddemann:Roche: Membership on an entity's Board of Directors or advisory committees; Genentech: Other: Grants; Roche: Other: Grants.
- Published
- 2016
- Full Text
- View/download PDF